Login | Register

FDA Step Closer To Approving Breast Cancer Drug “Palbociclib”

The pharmaceutical giant Pfizer has just announced that their drug "Palbociclib", a selective inhibitor of cyclin dependent kinases (CDK) 4 and 6, has just received Breakthrough Therapy designation by the United States Food and Drug Administration (FDA) for breast cancer treatment. Breast cancer is the most common cancer among women worldwide...

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *